Novel Drug-Delivery Systems Assignment Help & Online Tutoring
Novel drug delivery systems (NDDS) are dosage forms engineered to control where, when and how fast a drug is released in the body, such as controlled-release matrices, transdermal patches, liposomes, nanoparticles, implants and gastroretentive tablets. FLN Tutors (Freelancer Network) helps pharmacy students one-to-one with NDDS theory, release-kinetics calculations, formulation assignments, lab reports and exam answers, explained by tutors who have studied and taught pharmaceutical technology. This page maps the NDDS syllabus unit by unit, explains release mechanisms and kinetic models, works through three calculations with every figure rechecked, and lists where students lose marks. It is written for B.Pharm Semester VII, M.Pharm pharmaceutics, MPharm and PharmD students. For the physical pharmacy behind dosage forms, see our [Pharmaceutics](/subjects/pharmaceutics) page; for conventional tablets and excipients, see [Pharmaceutical Formulation](/subjects/pharmaceutical-formulation). Matched to a verified specialist who knows your course, your university's marking criteria, and your deadline.
Topics we cover
- Controlled Drug Delivery
- Targeted Drug Delivery
- Nanoparticles
- Liposomes
- Microspheres
- Microencapsulation
- Transdermal Drug Delivery
- Ocular Drug Delivery
- Nasal Drug Delivery
- Pulmonary Drug Delivery
- Implantable Drug Delivery
- Sustained Release Systems
- Controlled Release Systems
- Drug Carriers
- Nanomedicine
- Polymeric Drug Delivery
- Vesicular Drug Delivery
Online Novel Drug-Delivery Systems tutoring
FLN offers one-to-one online Novel Drug-Delivery Systems tutoring with verified subject specialists. Sessions focus on core theory, clinical application and exam preparation, including Controlled Drug Delivery, Targeted Drug Delivery, Nanoparticles and Liposomes, using your own course material, so you understand the subject and can apply it yourself.
Last updated
Levels we tutor
- Undergraduate
- Master's
- PhD
What are novel drug delivery systems?
A novel drug delivery system is any dosage form designed to do more than release its whole drug content at once. Conventional tablets and injections give a peak and a trough; NDDS aim to hold drug levels steadier, send the drug to a particular tissue, protect a fragile molecule, or cut the number of administrations a patient has to remember.
Quotable definition: NDDS are dosage forms that use a polymer, a carrier or a device to control the rate, the time or the site of drug release, so that the drug acts where it is needed for as long as it is needed.
| Family | Main idea | Typical examples studied |
|---|---|---|
| Controlled and sustained release | Slow, predictable release over hours or days | Matrix tablets, reservoir pellets, osmotic pumps |
| Targeted delivery | Carry the drug to a chosen organ, cell or receptor | Liposomes, niosomes, polymeric nanoparticles, antibody conjugates |
| Site-specific routes | Use a route that avoids the gut or first-pass metabolism | Transdermal patches, nasal and pulmonary systems, ocular inserts |
| Retention systems | Keep the dosage form at the absorption site longer | Floating tablets, mucoadhesive films, intrauterine systems |
| Long-acting depots | Release from inside the body for weeks or months | Biodegradable implants, in situ forming gels, microsphere depots |
Educational only: what this novel drug delivery systems page covers
Educational only. This page explains novel drug delivery systems at course level: concepts, syllabus topics, formulation science, calculations on fictional laboratory data, and how to write assignments and exam answers. It does not give dosing, treatment or clinical advice for any patient, and nothing here should be used to choose, change or stop a medicine. Questions about a real person's medicines belong with a doctor or pharmacist.
All worked examples below use invented formulation data, labelled as fictional, so the arithmetic can be checked without suggesting any real product's performance.
What does the NDDS syllabus cover?
In India the Pharmacy Council of India (PCI) B.Pharm syllabus places Novel Drug Delivery Systems in Semester VII as course BP704T. Its five units run roughly as follows; your university's order may differ slightly, so match it against your own handbook.
| Unit | Topics | Typical exam question |
|---|---|---|
| I | Controlled drug delivery: terminology, rationale, advantages and limits, drug properties that suit or rule out controlled release; polymers: classification, properties, uses | "Discuss the physicochemical and biological properties of drugs relevant to controlled release" |
| II | Microencapsulation methods; mucoadhesive drug delivery; implantable systems | "Explain coacervation-phase separation with a labelled diagram" |
| III | Transdermal systems; gastroretentive systems; nasal and pulmonary delivery | "Describe the evaluation of transdermal patches" |
| IV | Targeted delivery: liposomes, niosomes, nanoparticles, monoclonal antibodies | "Compare liposomes and niosomes" |
| V | Ocular delivery systems; intrauterine delivery systems | "Write a note on in situ gelling ophthalmic systems" |
At M.Pharm level the same ground returns in more depth in modern pharmaceutics and drug delivery courses, with added material on quality by design, regulatory filing of modified-release products and stability of nanocarriers. In the UK, US, Australia and Canada NDDS rarely appears as a stand-alone module; it sits inside pharmaceutics, pharmaceutical technology or drug delivery modules of MPharm, PharmD, BPharmSci and MSc pharmaceutical science programmes.
How is NDDS taught in the UK, US, Australia, Canada and India?
| Country | Where NDDS appears | How it is assessed |
|---|---|---|
| UK | MPharm pharmaceutics and drug delivery themes; MSc pharmaceutical science and drug delivery | Unseen exams, formulation design coursework, lab reports, integrated case studies built around GPhC learning outcomes |
| US | PharmD pharmaceutics and biopharmaceutics sequences; BS and graduate pharmaceutical sciences | Quizzes, problem sets on release kinetics, formulation projects; later NAPLEX questions touch modified-release labelling |
| Australia | Bachelor and Master of Pharmacy pharmaceutics units; pharmaceutical science degrees | Written exams, laboratory practicals and group formulation projects |
| Canada | Entry-to-practice PharmD pharmaceutics courses; graduate pharmaceutical sciences | Exams, lab reports and research-style assignments |
| India | PCI B.Pharm BP704T (Semester VII), M.Pharm pharmaceutics, Pharm.D pharmaceutics | University theory papers with long and short answers, sessional exams, practical records, M.Pharm seminars |
The science is the same everywhere; what changes is the format. Indian theory papers reward structured long answers with labelled diagrams, while UK and US coursework rewards design reasoning and data interpretation. Your tutor writes to the format your course uses.
Why control drug release at all?
Controlled release is justified when it solves a real problem with the conventional dose form. Course questions usually expect four or five of these reasons, each linked to a property of the drug.
- Fewer administrations. A drug cleared quickly needs frequent doses; slowing release can reduce how often it is taken, which helps adherence.
- Smaller swings in plasma level. Flatter profiles keep levels inside the therapeutic window for longer and away from the peaks linked to side effects.
- Protection of the drug. Encapsulation can shield peptides, proteins and nucleic acids from enzymes and pH.
- Site targeting. Delivering more of the drug to the target tissue can reduce exposure elsewhere.
- Route change. Skin, nose, lungs and eye routes bypass the gut and first-pass metabolism.
Markers also want the limits: dose dumping if the release mechanism fails, harder dose adjustment, higher cost, and drugs that do not suit the approach. Drugs with very long half-lives, very narrow absorption windows, poor solubility or very large doses are the usual poor candidates, and a good answer says why for each.
| Term | Meaning in exam answers |
|---|---|
| Sustained release | Release spread over a longer time than a conventional dose form |
| Controlled release | Release at a predictable, designed rate, often close to zero order |
| Delayed release | Release held back until a set time or site, such as an enteric coat |
| Extended release | Regulatory term for products that allow a reduced dosing frequency |
| Targeted release | Release concentrated at a chosen site or cell type |
Which polymers are used in NDDS, and how do you choose one?
Polymers carry most NDDS: they form the matrix, the membrane, the coat or the carrier. Exam answers classify them by origin, by degradability and by function.
| Polymer | Origin | Degradable? | Typical role |
|---|---|---|---|
| Hydroxypropyl methylcellulose (HPMC) | Semi-synthetic | No (swells and erodes) | Hydrophilic matrix tablets, mucoadhesive films |
| Ethylcellulose | Semi-synthetic | No | Insoluble coats and inert matrices |
| Poly(lactic-co-glycolic acid) (PLGA) | Synthetic | Yes, by hydrolysis | Microspheres, implants, nanoparticles |
| Chitosan | Natural (from chitin) | Yes | Mucoadhesive and nasal systems, nanoparticles |
| Sodium alginate | Natural (seaweed) | Yes | Beads, raft-forming and floating systems |
| Carbomers (cross-linked polyacrylic acid) | Synthetic | No | Mucoadhesive gels, ocular gels |
| Poloxamers | Synthetic | No | Thermo-responsive in situ gels |
| Polyethylene glycol (PEG) | Synthetic | No | Surface coating that lengthens nanocarrier circulation |
To choose a polymer, work through the release target, the route, the drug's solubility, the processing method (heat, solvent, compression), compatibility with the drug, regulatory acceptance and cost. PLGA, for example, lets a formulator tune degradation through its lactide-to-glycolide ratio and molecular weight, which is why it dominates depot microspheres and implants.
How do release mechanisms and kinetic models work?
Every NDDS releases drug by one or more physical mechanisms, and each mechanism leaves a fingerprint in the release data. Assignments usually ask you to fit dissolution data to several models and argue which mechanism dominates.
| Mechanism | What happens | Model it tends to fit |
|---|---|---|
| Diffusion through a matrix | Drug dissolves and diffuses out of an inert matrix; path length grows over time | Higuchi: Q = kH√t |
| Diffusion through a membrane (reservoir) | Constant concentration gradient across a rate-controlling membrane | Zero order: Q = k0t |
| Dissolution or erosion | The matrix or coat dissolves or erodes away | Zero order or Hixson-Crowell |
| Swelling | Polymer hydrates and forms a gel layer that controls diffusion | Korsmeyer-Peppas with n between the Fickian and case II limits |
| Osmotic pressure | Water enters a semipermeable shell and pushes drug out through an orifice | Zero order while solid drug remains |
| Concentration-dependent release | Rate falls as the remaining drug falls | First order: ln(remaining) falls linearly with t |
The Korsmeyer-Peppas equation, Mt/M∞ = ktⁿ, is fitted to the first 60% of release. For a thin film, n = 0.5 suggests Fickian diffusion and n = 1.0 suggests case II (relaxation-controlled) transport, with anomalous transport in between; cylinders and spheres have lower limits (about 0.45 and 0.89 for cylinders). Many students forget that the limits depend on geometry, and lose the mark.
How to fit release data, step by step: 1. Tabulate time and cumulative % released, corrected for sample withdrawal. 2. Transform the data for each model: % released against t, log % remaining against t, % released against √t, log fraction against log t. 3. Fit a straight line to each and record the slope and R². 4. Compare R² and, better still, the residuals and an information criterion such as AIC. 5. Name the mechanism and support it with the physics of your dosage form, not R² alone.
Worked example: zero-order, first-order and Higuchi release compared
Fictional data. Three experimental matrix tablets, A, B and C, each contain the same amount of a model drug. Their release follows three different models, with constants obtained from fitted lines:
- Tablet A (zero order): k0 = 5% per hour.
- Tablet B (first order): k1 = 0.1 per hour.
- Tablet C (Higuchi): kH = 12% per √hour.
Question: how much has each released at 8 hours, and how long does each take to release half its drug?
At 8 hours - A: Q = 5 × 8 = 40%. - B: fraction remaining = e^(−0.1 × 8) = e^(−0.8) = 0.4493, so released = 100 × (1 − 0.4493) = 55.07%. - C: Q = 12 × √8 = 12 × 2.828 = 33.94%.
Time to 50% released - A: t = 50 ÷ 5 = 10 hours. - B: t½ = ln 2 ÷ 0.1 = 6.93 hours. - C: √t = 50 ÷ 12 = 4.167, so t = 4.167² = 17.36 hours.
| Tablet | Model | Released at 8 h | Time to 50% |
|---|---|---|---|
| A | Zero order | 40% | 10 h |
| B | First order | 55.07% | 6.93 h |
| C | Higuchi | 33.94% | 17.36 h |
What the numbers tell you. The first-order tablet releases fastest early and then slows sharply; the zero-order tablet releases at a steady rate; the Higuchi matrix starts reasonably fast but slows as the diffusion path lengthens, so it takes longest to reach half. In an assignment you would add that the Higuchi equation only holds while the matrix still contains undissolved drug, and that a model with the best R² is not proof of mechanism.
How are microspheres, mucoadhesive and implantable systems made and tested?
These three Unit II topics are popular for long answers because each has a method list and an evaluation list.
Microencapsulation methods | Method | Principle | Suits | |---|---|---| | Coacervation-phase separation | Polymer separates from solution and coats dispersed drug droplets or particles | Gelatin and gum arabic coats | | Solvent evaporation | Drug and polymer in a volatile solvent are emulsified, then the solvent is removed | PLGA microspheres | | Spray drying | Solution or suspension atomised into hot air | Heat-tolerant drugs, inhalation powders | | Pan coating and air suspension (Wurster) | Coating sprayed onto moving particles | Larger particles and pellets | | Interfacial polymerisation | Monomers react at a droplet surface to form a shell | Capsule walls of polyamide type |
Evaluation covers particle size and shape (optical microscopy, SEM), yield, drug content, encapsulation efficiency, surface morphology and in vitro release.
Mucoadhesion is explained by several theories: wetting, electronic, adsorption, diffusion-interlocking and fracture. A good answer names at least four, links each to a polymer property (chain flexibility, hydrogen-bonding groups, charge, hydration) and lists the test methods: tensile detachment force, rheological synergism and ex vivo residence time on mucosa.
Implants may be non-degradable reservoirs that need removal, or biodegradable matrices of polymers such as PLGA that erode in place. In situ forming implants are injected as liquids and set in the body. Evaluation covers drug content, release in buffer over weeks, polymer degradation, sterility and, for degradable types, the acid microclimate that builds up as polyesters break down.
What makes transdermal delivery work?
Transdermal systems deliver drug through intact skin into the circulation. The stratum corneum, a thin layer of dead, lipid-sealed cells, is the main barrier, so only some drugs suit the route.
Drug properties that suit transdermal delivery: low molecular weight (often quoted as under about 500 daltons), moderate lipophilicity so the drug can cross both lipid and aqueous layers, high potency so a small amount is enough, and no skin irritation.
| Patch design | How release is controlled | Notes for exams |
|---|---|---|
| Reservoir (membrane-controlled) | A rate-controlling membrane sits between a drug reservoir and the skin | Near zero-order release; risk of dose dumping if the membrane is damaged |
| Matrix (drug-in-adhesive) | Drug dispersed in the adhesive layer itself | Thinner, simpler; release slows as the matrix depletes |
| Multi-laminate drug-in-adhesive | Several adhesive layers with different drug loads | Finer control of the release profile |
| Micro-reservoir | Drug suspended in microscopic pockets within a polymer | Combines reservoir and matrix features |
Penetration enhancement is a standard sub-question. Chemical enhancers (ethanol, propylene glycol, fatty acids such as oleic acid, terpenes, surfactants) disturb stratum corneum lipids. Physical methods include iontophoresis, sonophoresis, electroporation and microneedles.
Evaluation of patches: thickness, weight uniformity, drug content, moisture content and uptake, folding endurance, tensile strength, peel adhesion, tack, in vitro release, and skin permeation studied in Franz diffusion cells.
Worked example: transdermal flux from Fick's first law
Fictional data. In a Franz diffusion cell study, a gel holds a model drug at a donor concentration Cv = 5 mg/mL, kept effectively constant (infinite dose). The fitted permeability coefficient across the membrane is Kp = 2 × 10⁻³ cm/h. The patch planned from this gel has an active area of 10 cm².
Question: find the steady-state flux, the delivery rate from the whole patch, and the amount delivered over 24 hours.
Step 1: steady-state flux. Under sink conditions Fick's first law gives J = Kp × Cv. J = 0.002 cm/h × 5 mg/cm³ = 0.01 mg/cm²/h, which is 10 µg/cm²/h.
Step 2: delivery rate from the patch. Rate = J × area = 0.01 × 10 = 0.1 mg/h, or 100 µg/h.
Step 3: amount over 24 hours. 0.1 mg/h × 24 h = 2.4 mg.
Step 4: link back to Kp. Kp = D × K ÷ h, where D is the diffusion coefficient in the membrane, K the membrane-vehicle partition coefficient and h the membrane thickness. Doubling the partition coefficient doubles Kp and so doubles flux, which is why enhancers and vehicle choice matter.
| Quantity | Formula | Value |
|---|---|---|
| Flux J | Kp × Cv | 10 µg/cm²/h |
| Patch delivery rate | J × A | 100 µg/h |
| Delivered in 24 h | rate × t | 2.4 mg |
In a real permeation report you would also estimate the lag time from the x-intercept of the cumulative amount against time plot, and state that these are in vitro figures for an invented gel, not a claim about any product.
How do liposomes, niosomes and nanoparticles target drugs?
Unit IV is usually the highest-scoring unit because it carries long comparison questions. Targeting is described at three levels: to an organ, to a cell type, and to a structure inside the cell.
| Carrier | Made from | Strengths | Weak points to mention |
|---|---|---|---|
| Liposomes | Phospholipid bilayers, often with cholesterol | Carry both water-soluble (core) and lipid-soluble (bilayer) drugs; biocompatible | Leakage, oxidation of lipids, cost, short shelf life |
| Niosomes | Non-ionic surfactants with cholesterol | Cheaper, more chemically stable than liposomes | Aggregation and drug leakage on storage |
| Polymeric nanoparticles | PLGA, polylactide, chitosan and others | Sustained release; surface can be modified | Residual solvent, scale-up |
| Solid lipid nanoparticles and nanostructured lipid carriers | Solid lipids, or blends of solid and liquid lipids | Avoid organic solvents; good for lipophilic drugs | Drug expulsion on storage (less in NLCs) |
| Polymeric micelles | Amphiphilic block copolymers | Solubilise poorly soluble drugs | Can dissociate on dilution |
| Antibody-drug conjugates and monoclonal antibodies | Antibody linked to a drug | Cell-level targeting through an antigen | Complex manufacture, immunogenicity |
Passive targeting relies on size: leaky vessels and poor lymphatic drainage in some tumours let nanocarriers accumulate, the enhanced permeability and retention (EPR) effect. Active targeting adds a ligand, such as an antibody, folate or a peptide, that binds a receptor on the target cell. PEG coating ("stealth" carriers) slows removal by the mononuclear phagocyte system.
Characterisation answers markers expect: particle size and polydispersity index by dynamic light scattering, zeta potential for stability, morphology by TEM or SEM, entrapment efficiency, drug loading, in vitro release, and stability on storage.
Liposome preparation methods to list: thin-film hydration (the classic Bangham method), reverse-phase evaporation, ethanol injection, ether injection, detergent removal and extrusion or sonication for size reduction. Vesicles are classed as multilamellar (MLV), small unilamellar (SUV) and large unilamellar (LUV).
Worked example: liposome entrapment efficiency and drug loading
Fictional data. A batch of liposomes is prepared with 20 mg of a model drug and 100 mg of total lipid. After separating the vesicles by centrifugation, the supernatant contains 6 mg of free (unentrapped) drug.
Step 1: entrapped drug. 20 − 6 = 14 mg.
Step 2: entrapment efficiency (EE). EE = entrapped ÷ total added × 100 = 14 ÷ 20 × 100 = 70%.
Step 3: drug loading (DL). Definitions differ between textbooks, so state which one you use: - DL as drug per total vesicle mass = 14 ÷ (14 + 100) × 100 = 12.28%. - DL as drug-to-lipid ratio = 14 ÷ 100 = 0.14, written 14% w/w.
Step 4: what if free drug were under-measured? If incomplete separation left some free drug in the pellet and the supernatant showed only 4 mg, EE would read 16 ÷ 20 × 100 = 80%: a 10-point overestimate from a method error. This is why markers want the separation method (ultracentrifugation, dialysis, size-exclusion columns) stated and validated.
| Quantity | Working | Result |
|---|---|---|
| Entrapped drug | 20 − 6 | 14 mg |
| Entrapment efficiency | 14 ÷ 20 × 100 | 70% |
| Drug loading (mass basis) | 14 ÷ 114 × 100 | 12.28% |
| EE if free drug read as 4 mg | 16 ÷ 20 × 100 | 80% |
Indirect methods (measuring free drug) and direct methods (lysing vesicles with a solvent or detergent and measuring entrapped drug) should agree within experimental error; a lab report that uses both and compares them earns more credit.
How do gastroretentive, nasopulmonary, ocular and intrauterine systems work?
These four topics share an idea: keep the drug at the absorption site longer, or use a route that the gut cannot offer.
Gastroretentive systems hold a dosage form in the stomach to help drugs absorbed mainly in the upper small intestine or acting locally in the stomach. | Approach | Mechanism | Evaluation | |---|---|---| | Floating (effervescent) | Bicarbonate releases carbon dioxide, lowering density below gastric fluid | Floating lag time, total floating time | | Floating (non-effervescent) | Swelling hydrocolloids form a low-density gel | Buoyancy, swelling index | | Mucoadhesive | Adheres to gastric mucosa | Detachment force, residence time | | Swelling and expanding | Grows too large to pass the pylorus | Swelling kinetics, mechanical strength | | High density | Sinks to the bottom of the stomach | Density measurement |
Nasal and pulmonary delivery avoids first-pass metabolism and gives fast onset. Answers should cover nasal anatomy, mucociliary clearance as the main barrier, absorption enhancers and mucoadhesive polymers. For the lungs, aerodynamic particle size decides deposition, and the device types are pressurised metered-dose inhalers, dry powder inhalers and nebulisers, each tested with cascade impactors.
Ocular delivery fights rapid tear turnover and drainage. Options include viscosity enhancers, in situ gels that set on contact with the eye (pH-triggered, temperature-triggered with poloxamers, or ion-activated with gellan gum), ocular inserts, and nanocarriers.
Intrauterine systems release a drug locally from a device in the uterus over a long period. Exam answers describe the device structure, the release-controlling membrane and the advantages of local delivery, at a conceptual level.
Where do students lose marks in NDDS?
From marking and tutoring NDDS answers, the same errors cost marks every term:
| Mistake | Why it costs marks | Do this instead |
|---|---|---|
| Listing advantages without limits | Answers look one-sided | Give at least three limits, with dose dumping first |
| Choosing a kinetic model by R² alone | Several models can fit well | Add residuals, AIC and the physics of the dosage form |
| Fitting Korsmeyer-Peppas to the whole curve | The model holds only to about 60% release | Truncate the data and say so |
| Using thin-film n limits for a tablet | Limits depend on geometry | Quote cylinder or sphere limits as appropriate |
| Confusing entrapment efficiency with drug loading | Two different ratios | Define both, with formulas, before calculating |
| Unlabelled diagrams of patches or liposomes | Diagrams carry fixed marks in Indian papers | Label every layer: backing, reservoir, membrane, adhesive, liner |
| Writing "nanoparticles cross every barrier" | Overclaims fail critical-thinking criteria | Name the barrier and the evidence |
| Missing evaluation tests | Every system has an evaluation list | End each system with its quality tests |
A further habit that loses marks in UK and US coursework: copying a release profile from a paper without saying which apparatus, medium and sampling plan produced it.
What do markers look for in NDDS assignments and exams?
Markers in pharmaceutics look for the same five things whatever the format:
- Correct definitions in the first lines. Controlled, sustained, delayed and targeted release are not interchangeable.
- Mechanism linked to design. Say why the polymer, the size or the device produces the release you claim.
- Labelled diagrams. A transdermal patch cross-section or liposome bilayer drawn and labelled earns marks quickly.
- Evaluation tests. Name each test and what it shows.
- Critical comment. Limits, stability, scale-up and regulatory concerns separate a first-class or distinction answer from a pass.
How to plan a 10-mark NDDS long answer: 1. Define the system in one or two sentences. 2. Give the rationale and two or three advantages. 3. Draw and label the structure or the process. 4. Describe preparation methods, one line each. 5. List evaluation parameters. 6. Close with limits and one current application.
For a formulation design project, markers add a sixth check: is the quality target product profile clear, and do your critical quality attributes follow from it? See our Pharmaceutical Engineering page for scale-up and process questions that often accompany NDDS projects.
Which tools and software do NDDS students use?
| Tool | Used for |
|---|---|
| USP dissolution apparatus 1 to 7 (basket, paddle, reciprocating cylinder, flow-through cell, paddle over disc, rotating cylinder, reciprocating holder) | Release testing; apparatus 5 and 6 for transdermal systems, 4 for microspheres and implants |
| Franz diffusion cells | Skin and membrane permeation |
| Dynamic light scattering and zeta potential analysers | Nanocarrier size, polydispersity and surface charge |
| SEM and TEM | Morphology of microspheres and nanoparticles |
| DSC, XRD and FTIR | Drug-polymer compatibility and crystallinity |
| Texture analysers | Mucoadhesion force, gel strength, patch tack |
| Cascade impactors | Aerodynamic size of inhaled particles |
| Excel and dissolution add-ins such as DDSolver | Fitting zero-order, first-order, Higuchi and Korsmeyer-Peppas models; f-factors |
| Design-Expert, Minitab, JMP | Factorial and response-surface designs for quality by design |
| GraphPad Prism, Origin | Release plots, regression and statistics |
| ImageJ | Measuring particle sizes from micrographs |
| ChemDraw | Polymer and drug structures for reports |
A tutor can work inside your own spreadsheet, show you how to set up each model transform, and check that your fitted constants match your plots. For regression and statistical tests behind formulation studies, our Biostatistics page goes further.
Which NDDS assignments do we help with?
| Task | Typical level | What help looks like |
|---|---|---|
| Long-answer exam preparation (BP704T) | B.Pharm Semester VII | Model answer plans, diagram practice, timed answers marked against the paper pattern |
| Release-kinetics problem sets | B.Pharm, MPharm, PharmD | Data transformations, model fitting and interpretation, step by step |
| Lab reports on matrix tablets, microspheres or patches | Undergraduate practicals | Structure, calculations, discussion of deviations, referencing |
| Formulation design project | MPharm, M.Pharm | QTPP, CQAs, factorial design, response surfaces |
| Review article or seminar on a carrier | M.Pharm, MSc | Search strategy, structure, critical synthesis |
| Dissertation chapters on nanocarriers | M.Pharm, MSc, early PhD | Methods, characterisation data, statistics |
For broader dosage-form work, see Pharmaceutical Formulation; for absorption and BCS questions linked to modified release, see Biopharmaceutics; for plasma-level modelling, see Pharmacokinetics.
How does an NDDS tutoring session work?
- Send the brief. Upload the question, marking rubric, lab data or syllabus unit through the quote form, with your deadline and university.
- Free quote. You receive a quote and the tutor's relevant background before you pay.
- Diagnose first. The first session checks what you already know: definitions, kinetic models, which units feel weakest.
- Work through your material. The tutor shares a screen or whiteboard, works through one example fully, then has you do the next one while they watch.
- Written follow-up. You get notes, worked steps or annotated feedback on your draft.
- Revision. Free revisions within the original brief follow the published policy.
Delivery options on the site run from 3-hour and 6-hour to 12-hour, same-day (24-hour) and 48-hour, so urgent exam revision can be booked quickly. Book live one-to-one tutoring or ask for homework help.
How much does NDDS help cost?
There is no fixed price on this page because the cost depends on the task: the level (B.Pharm, M.Pharm, MPharm or PharmD), the length, the amount of data analysis, and the deadline. A short release-kinetics problem set costs less than a formulation design project with a factorial study.
To find out, send your brief for a free quote. You see the price before you pay anything, and live tutoring is charged by the hour at the tutor's rate. For NDDS orders, refunds and free revisions within the brief are handled under the refund policy. The fastest way to keep cost down is to send the full brief, rubric and data at the start, so the tutor can quote accurately.
Using NDDS help within your course rules
Tutoring that explains concepts, checks your calculations and gives feedback on your own drafts is the same kind of support a lecturer or lab demonstrator gives, and most universities allow it. Handing in a formulation report or seminar file prepared by another person is not permitted. Read your university's academic integrity policy, tell your tutor about any limits (for example, a take-home exam), and use worked solutions to learn the method, then write your own answer.
All work is written from scratch and is plagiarism-free, and your files stay 100% confidential. Laboratory data you send is used only for your sessions.
Stuck on a Novel Drug-Delivery Systems question?
Send it to a Novel Drug-Delivery Systems tutor for step-by-step working. The quote is free.
What you get
Every Novel Drug-Delivery Systems order includes
- Written from scratch to your exact brief
- Fully referenced in your required citation style
- Plagiarism-checked before delivery
- Free revisions until you are satisfied
- 100% confidential — your privacy protected
Simple process
How your Novel Drug-Delivery Systems help works
Describe your Novel Drug-Delivery Systems task
Tell us your assignment brief, word count, deadline, and academic level. The more detail, the better the match.
Matched to a specialist
We pair you with a Novel Drug-Delivery Systems expert whose background aligns with your specific topic and university requirements.
Delivered, checked, revised
Your work arrives before the deadline, plagiarism-checked. Free revisions until it meets your exact requirements.
Takes about two minutes. The quote is free.
Student reviews
What students say about Novel Drug-Delivery Systems help
Used FLN Tutors? Be one of the first to share how it went, in writing or in a short video.
Novel Drug-Delivery Systems tutoring: frequently asked questions
What is the difference between novel drug delivery systems and conventional dosage forms?
Conventional dosage forms release the whole dose quickly, producing peaks and troughs in drug levels. Novel drug delivery systems use polymers, carriers or devices to control the rate, timing or site of release, aiming for steadier levels, fewer administrations, protection of fragile drugs or delivery to a chosen tissue.
Which units are in the B.Pharm NDDS syllabus BP704T?
The PCI syllabus covers controlled release and polymers, microencapsulation, mucoadhesive and implantable systems, transdermal, gastroretentive and nasopulmonary systems, targeted delivery with liposomes, niosomes, nanoparticles and monoclonal antibodies, and ocular and intrauterine systems. Check your own university handbook, because the order of topics can differ slightly.
How do I know which release kinetic model fits my data?
Transform your data for each model, fit straight lines and compare R², residuals and an information criterion such as AIC. Then check the physics: an inert matrix suggests Higuchi diffusion, a reservoir membrane suggests zero order. Fit Korsmeyer-Peppas only to the first 60 percent of release and use the correct geometry limits.
What does the Korsmeyer-Peppas exponent n tell me?
The exponent n indicates the release mechanism. For a thin film, n of 0.5 points to Fickian diffusion, 1.0 to case II relaxation-controlled transport, and values between to anomalous transport. Cylinders and spheres have lower limits, so state your tablet geometry before interpreting n in an assignment or viva.
What is the difference between liposomes and niosomes?
Both are vesicles with a bilayer that can carry water-soluble and lipid-soluble drugs. Liposomes are built from phospholipids, usually with cholesterol; niosomes use non-ionic surfactants with cholesterol. Niosomes are cheaper and more chemically stable, while liposomes are closer to natural membranes. Exams usually expect a comparison table covering structure, stability and cost.
How do you calculate entrapment efficiency?
Subtract the free, unentrapped drug from the total drug added, divide by the total added and multiply by 100. For example, 14 mg entrapped from 20 mg added gives 70 percent. State your separation method, because incomplete separation of free drug inflates the result, and keep entrapment efficiency distinct from drug loading.
What is the EPR effect in targeted drug delivery?
The enhanced permeability and retention effect describes how nanocarriers can build up in some tumours because their blood vessels are leaky and lymphatic drainage is poor. It is a form of passive targeting. Good answers add that the effect varies widely between tumours and models, which limits how far it can be relied on.
Why are only some drugs suitable for transdermal patches?
The stratum corneum lets through mainly small, moderately lipophilic, potent molecules. Drugs that are large, highly water-soluble, needed in large amounts or irritating to skin are poor candidates. Course answers usually cite molecular weight under about 500 daltons, a balanced partition coefficient and high potency as the main requirements.
How are transdermal patches evaluated?
Typical tests include thickness, weight uniformity, drug content, moisture content and uptake, folding endurance, tensile strength, peel adhesion and tack, in vitro release, and permeation through skin or synthetic membranes in Franz diffusion cells. Long answers should explain what each test shows, not only list the names.
What is a gastroretentive drug delivery system?
It is a dosage form designed to stay in the stomach longer than normal so a drug is released above its absorption site or acts locally. Approaches include floating effervescent and non-effervescent systems, mucoadhesive systems, swelling and expanding systems and high-density systems, each evaluated with its own buoyancy, adhesion or swelling tests.
Can someone help me with my NDDS assignment?
Yes. FLN Tutors matches you with a pharmacy tutor who explains the topic, works through release-kinetics or entrapment calculations with you, and gives feedback on your own draft. Send the brief, rubric and any lab data through the quote form, and you will see the tutor's background and a free quote first.
What do I get when I book NDDS help?
You get one-to-one explanation from a tutor with pharmaceutics experience, worked steps for the calculations in your brief, annotated feedback on your draft or lab report, and notes you can revise from. Live sessions use screen sharing, so the tutor can work inside your own spreadsheet, data and diagrams.
How fast can I get help with novel drug delivery systems?
Delivery options on the site include 3-hour, 6-hour, 12-hour, same-day and 48-hour turnaround, so urgent questions before an exam can be handled quickly. Longer tasks such as a formulation design project or dissertation chapter need more time, and the quote states the delivery date before you confirm the booking.
How much does help with NDDS coursework cost?
The cost depends on your level, the length of the task, the amount of data analysis and the deadline. No prices are listed on this page. Upload your NDDS brief for a free quote; the cost is shown before any payment. Live tutoring is charged hourly at the tutor's rate, and refunds follow the published policy.
Is it allowed to get tutoring for a pharmacy course module?
Tutoring that explains concepts and reviews your own work is generally allowed, much like help from a lecturer or demonstrator. Submitting work someone else wrote as your own is not. Check your university's academic integrity policy and tell your tutor about any restrictions, such as take-home exams, so sessions stay within them.
Will my lab data and assignment be kept confidential?
Yes. Your files, lab data and university details are used only for your sessions and are never shared or published. If your project uses data from a supervisor's ongoing research, ask them before sending it, or share a version with the identifying details removed, since the tutor needs the structure rather than the confidential values.
Do you help with M.Pharm seminars on nanocarriers?
Yes. Tutors help you choose a focused topic, build a literature search, structure the seminar around preparation, characterisation, release and limits, and design clear slides with labelled figures. They also run practice questioning so you can defend points on particle size, zeta potential, stability and scale-up when examiners probe your understanding.
Which polymers come up most in NDDS exams?
HPMC, ethylcellulose, PLGA, chitosan, sodium alginate, carbomers, poloxamers and polyethylene glycol appear most often. Learn each one's origin, whether it degrades, and its main role, such as hydrophilic matrix, insoluble coat, depot microsphere, mucoadhesive or thermo-responsive gel. A short comparison table answers many polymer questions well.
How should I draw a transdermal patch diagram for exams?
Draw the layers in order from outside to skin: backing film, drug reservoir or drug-in-adhesive matrix, rate-controlling membrane where present, adhesive layer and release liner. Label every layer, add an arrow showing drug movement into skin, and draw reservoir and matrix designs side by side when the question asks for types.
Do I need hands-on lab work to understand NDDS?
Lab work helps, especially for dissolution testing, patch evaluation and liposome preparation, but much of the course is theory and calculation you can master away from the lab. A tutor can explain what each test measures and why results vary, so you write sharper discussion sections when your practical data look unexpected.
Question not answered here?
Not sure which service you need?
Tell us your assignment brief and deadline — we'll match you with the right expert and service instantly.
Money-Back Guarantee
Full refund if we miss the agreed deadline, can't find a suitable expert, or major errors can't be fixed by revision.
Learn more →100% Confidential
Your identity, order details and institution are never shared with any third party.
Learn more →Deadline-Backed Delivery
Every order has an agreed deadline. If we don't deliver by it, you can claim a full refund.
Learn more →Get started today
Ready to get expert help?
Tell us what you need and get matched with a tutor who teaches your subject. Delivered on time, every time.
